This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene (CNC) Wins Contract to Serve Texas' Foster Population
by Zacks Equity Research
Centene's (CNC) Texas subsidiary secures a contract to continue catering to the state's foster children and youth via its Medicaid plans.
ASRT vs. STVN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. STVN: Which Stock Is the Better Value Option?
Is Most-Watched Stock Assertio Holdings, Inc. (ASRT) Worth Betting on Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.
Assertio (ASRT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed at $2.74 in the latest trading session, marking a +1.3% move from the prior day.
Pacira (PCRX) Up on Data From Exparel Label Expansion Study
by Zacks Equity Research
Pacira (PCRX) reports encouraging top-line data from the phase III study evaluating Exparel as a single-dose femoral nerve block in the adductor canal for total knee arthroplasty. Shares rise.
Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
Assertio (ASRT) Upgraded to Buy: Here's Why
by Zacks Equity Research
Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Erytech (ERYP) Stops Developing Drug in Leukemia, Down 19.6%
by Zacks Equity Research
After evaluating the FDA's feedback, Erytech Pharma (ERYP) halts developing its lead candidate in leukemia. It is also looking for strategic partnerships to leverage its proprietary platform.
5 Cheap Healthcare Stocks in 2022
by Tracey Ryniec
Energy, banks and agriculture have plenty of value stocks this year but what about healthcare?
AbbVie (ABBV), J&J's Imbruvica Gets FDA Nod for cGVHD in Kids
by Zacks Equity Research
AbbVie (ABBV) and J&J's (JNJ) Imbruvica gets FDA nod for label expansion to treat pediatric patients with chronic graft versus host disease. It is also the first BTK inhibitor approved for use in pediatric patients
BioMarin's (BMRN) Hemophilia Gene Therapy Gets Nod in EU
by Zacks Equity Research
BioMarin's (BMRN) Roctavian is the first gene therapy to get approval for hemophilia A in the European Union. The therapy has also been granted a 10-year market exclusivity.
ASRT or CORT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. CORT: Which Stock Is the Better Value Option?
Are Medical Stocks Lagging Axonics (AXNX) This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and Assertio (ASRT) have performed compared to their sector so far this year.
Jazz (JAZZ) Starts Study on Epidiolex for a Fourth Indication
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) initiates a two-part pivotal late-stage study evaluating its epilepsy drug, Epidiolex, in children and adolescents suffering from epilepsy with Myoclonic-Atonic Seizures (EMAS).
Assertio (ASRT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of 100% and 11.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Shockwave Medical (SWAV) have performed compared to their sector so far this year.
ASRT vs. CTLT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. CTLT: Which Stock Is the Better Value Option?
Assertio (ASRT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Assertio Holdings' (ASRT) second-quarter performance is likely to reflect the sales performance of its marketed drugs and cost savings from the company's restructuring plans.
Assertio (ASRT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $3.11, moving +1.97% from the previous trading session.
Zacks.com featured highlights Assertio, Mercer International, and LGL
by Zacks Equity Research
Assertio, Mercer International, and LGL have been highlighted in this Screen of the Week article.
3 Best Breakout Stocks to Invest in for Attractive Returns
by Tirthankar Chakraborty
Assertio (ASRT), Mercer International (MERC) and The LGL Group (LGL) have been selected as the breakout stocks for today.
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Assertio (ASRT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $2.82, moving +0.71% from the previous trading session.
Centene (CNC) Divests Unit to Boost Focus on Core Business
by Zacks Equity Research
Centene (CNC) closes the deal to divest its pharmacy business. CNC primarily intends to pursue share repurchases with proceeds received from the transaction.
Here's Why Viracta Therapeutics (VIRX) is Up So Far This Year
by Zacks Equity Research
Viracta Therapeutics' (VIRX) Nana-val is being evaluated in multiple clinical studies in various subtypes of EBV-associated cancers.